A new Phase II clininical trial for the safety and effectiveness
of consensus interferon for chronic myelogenous leukemia (CML)
will be done in Denver at the University of Colorado Health Sciences
Center. Patient eligibility criteria, additional information, and contact
forms for patient enrollment can be found at:
http://www.centerwatch.com/studies/STU7460.HTM
Robert W. Neill, Jr.
Editor & Publisher
CML-L (The Chronic Myelogenous Leukemia List)
http://rwneill.com
=====
CML-L@USA.NET (Chronic Myelogenous Leukemia List)
Robert W. Neill, Jr., Editor & Publisher rob@rwneill.com
CML Web Page: http://rwneill.com
Subscribe/unsubscribe messages to CML-L@USA.NET
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
